Independent hematology practices are increasingly associating with larger practices and hospitals to remain financially viable. Touchpoint can help your customers ensure continuity of care during a time of transition.
While in the past hematology was practiced predominantly in small, community-based practices, the changing healthcare environment has driven an increasing number of hematology practices to associate with larger practices or hospitals. The reasons underlying this change are due to the high percentage of time hematologists spend on nonreimbursable patient care issues, as well as the increasing requirements for documentation and obtaining payer approval for treatment. Taken together, the increased administrative requirements and the high percentage of nonreimbursable time inherent in the practice of hematology are making independent hematology practices financially unrealistic.
Nevertheless, the field of hematology is advancing rapidly. New drug-development efforts are centered on immunotherapies for hematologic malignancy. There is also a pipeline of new medications for hemophilia, sickle cell anemia, and other hematologic illnesses.
During this time of structural change, continuity of care and the integrity of the doctor-patient relationship are key concerns. As such, hematologists will benefit most from:
- Education on newly introduced medications
- Assistance with patient education for rare hematologic diseases, such as sickle cell anemia and myelodysplastic syndrome
- Assistance with treatment authorizations to give patients access to needed medications and to decrease administrative workload
- Maintaining formulary access to medications for existing patients as practice organization changes
To support hematology practices in a time of transition, Touchpoint can assist your customers in maintaining a stable care environment for their patients through healthcare commercialization that meets their specific needs and eases their administrative burden.
Our medical science liaisons can provide physician education on the scientific aspects of emerging treatments, and our clinical health educators can provide the required patient education for rare hematologic conditions.